TRCT
HRTX icon

Tower Research Capital (TRC)’s Heron Therapeutics HRTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2K Buy
31,482
+12,089
+62% +$14K ﹤0.01% 3317
2025
Q4 		$25.2K Buy
19,393
+7,880
+68% +$9.73K ﹤0.01% 2923
2025
Q3 		$14.5K Sell
11,513
-3,668
-24% -$5.82K ﹤0.01% 3597
2025
Q2 		$31.4K Buy
15,181
+8,554
+129% +$17.5K ﹤0.01% 3362
2025
Q1 		$14.5K Sell
6,627
-2,258
-25% -$4.38K ﹤0.01% 3289
2024
Q4 		$13.6K Sell
8,885
-5,155
-37% -$8.36K ﹤0.01% 3518
2024
Q3 		$27.9K Buy
14,040
+3,528
+34% +$8.42K ﹤0.01% 3047
2024
Q2 		$36.8K Buy
10,512
+9,647
+1,115% +$29.6K ﹤0.01% 3331
2024
Q1 		$2.4K Sell
865
-12,564
-94% -$31.6K ﹤0.01% 5047
2023
Q4 		$22.8K Sell
13,429
-621
-4% -$684 ﹤0.01% 3567
2023
Q3 		$14.5K Buy
14,050
+6,132
+77% +$8.73K ﹤0.01% 3678
2023
Q2 		$9.19K Sell
7,918
-130
-2% -$232 ﹤0.01% 4325
2023
Q1 		$13K Buy
8,048
+3,239
+67% +$8.11K ﹤0.01% 3973
2022
Q4 		$12K Sell
4,809
-66,361
-93% -$214K ﹤0.01% 3715
2022
Q3 		$301K Buy
71,170
+32,550
+84% +$127K ﹤0.01% 1547
2022
Q2 		$108K Buy
38,620
+11,621
+43% +$46.7K ﹤0.01% 2224
2022
Q1 		$155K Buy
26,999
+813
+3% +$5.95K ﹤0.01% 1918
2021
Q4 		$239K Sell
26,186
-19,807
-43% -$202K ﹤0.01% 1623
2021
Q3 		$492K Buy
45,993
+42,008
+1,054% +$511K 0.01% 1002
2021
Q2 		$62K Sell
3,985
-18,634
-82% -$296K ﹤0.01% 2839
2021
Q1 		$367K Buy
22,619
+20,422
+930% +$364K 0.01% 1492
2020
Q4 		$46K Sell
2,197
-2,401
-52% -$41.7K ﹤0.01% 3196
2020
Q3 		$68K Sell
4,598
-5,269
-53% -$82.2K ﹤0.01% 3400
2020
Q2 		$146K Buy
+9,867
New +$162K 0.01% 2100
2020
Q1 		– Sell
-4,593
Closed -$108K – 3420
2019
Q4 		$108K Sell
4,593
-830
-15% -$18.4K 0.01% 891
2019
Q3 		$100K Buy
+5,423
New +$99.8K 0.01% 1345
2019
Q1 		– Sell
-40
Closed -$1K – 3997
2018
Q4 		$1K Sell
40
-228
-85% -$6.27K ﹤0.01% 3608
2018
Q3 		$8K Sell
268
-3,634
-93% -$135K ﹤0.01% 2879
2018
Q2 		$152K Sell
3,902
-1,924
-33% -$61.3K 0.01% 1196
2018
Q1 		$160K Buy
5,826
+5,725
+5,668% +$130K 0.01% 990
2017
Q4 		$2K Sell
101
-5,403
-98% -$88.1K ﹤0.01% 3207
2017
Q3 		$89K Buy
+5,504
New +$86.3K 0.01% 1470
2017
Q2 		– Sell
-200
Closed -$2.9K – 3024
2017
Q1 		$3K Buy
200
+120
+150% +$1.66K ﹤0.01% 2470
2016
Q4 		$1K Sell
80
-262
-77% -$4.11K ﹤0.01% 3610
2016
Q3 		$6K Sell
342
-1,002
-75% -$18.6K ﹤0.01% 2421
2016
Q2 		$24K Buy
1,344
+844
+169% +$16.5K ﹤0.01% 2091
2016
Q1 		$9K Buy
500
+447
+843% +$8.82K ﹤0.01% 2050
2015
Q4 		$1K Buy
+53
New +$1.42K ﹤0.01% 4085
2015
Q3 		– Sell
-880
Closed -$27K – 4329
2015
Q2 		$27K Sell
880
-1,136
-56% -$21.4K ﹤0.01% 1841
2015
Q1 		$29K Buy
2,016
+406
+25% +$4.58K ﹤0.01% 1933
2014
Q4 		$16K Buy
1,610
+1,592
+8,844% +$13K ﹤0.01% 1746
2014
Q3 		$0 Sell
18
-5,133
-100% -$47.8K ﹤0.01% 4600
2014
Q2 		$64K Buy
5,151
+4,028
+359% +$48.1K 0.01% 1137
2014
Q1 		$16K Buy
+1,123
New +$15K ﹤0.01% 2111

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Tower Research Capital (TRC)'s HRTX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Heron Therapeutics (HRTX) stake by 62% in Q1 2026, buying an estimated $14K and bringing the position to 31,482 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

Tower Research Capital (TRC) first reported a position in HRTX in Q1 2014 and has held it in 44 quarters since. The position peaked at $492K in Q3 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Tower Research Capital (TRC) held 31,482 shares of Heron Therapeutics worth $25.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 12,089 Heron Therapeutics shares in Q1 2026, an estimated $14K.
  • Heron Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3317 holding.
  • Tower Research Capital (TRC) first reported a position in Heron Therapeutics in Q1 2014 and has held it in 44 quarters since.
  • Tower Research Capital (TRC)'s Heron Therapeutics position peaked at $492K in Q3 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.